Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...

The former COO of franchisee DMD Ventures accused the company’s co-founders of using corporate funds to pay for lavish ...

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

The former chief operating officer of several high-volume Twin Peaks restaurants is suing his business partners, alleging ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a ...

Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Dr. Mitzi Morris, a distinguished dentist in Roswell, GA, has been honored as a 2025 Top Patient Rated Dentist by Find Local ...